Monte Rosa Therapeutics Inc (GLUE)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $800.67M
Last updated: Nov 17, 2026 at 11:05 AM ET
Monte Rosa Therapeutics Inc (GLUE) Competitors
The companies most similar to Monte Rosa Therapeutics are Rigel Pharmaceuticals (RIGL), Structure Therapeutics Inc. American Depositary Shares (GPCR) and Oric Pharmaceuticals (ORIC). By market cap, Monte Rosa Therapeutics ranks 10th of the 13 companies on this page; Structure Therapeutics Inc. American Depositary Shares (GPCR) is the largest at $1.43B.
Peer Comparison
GLUE's revenue growth of 325.8% is above the peer median of 0.0%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Monte Rosa Therapeutics (GLUE) | $800.67M | N/A | 13.3x | -186.2% | N/A | 325.8% | 0.00% |
| Rigel Pharmaceuticals Inc (RIGL) | $837.18M | 14.2x | 2.8x | 106.6% | 16.7% | 16.5% | 0.00% |
| Structure Therapeutics Inc. American Depositary Shares (GPCR) | $1.43B | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Oric Pharmaceuticals Inc (ORIC) | $814.71M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Mineralys Therapeutics, Inc. Common Stock (MLYS) | $1.36B | N/A | N/A | 0.0% | -51.1% | 0.0% | 0.00% |
| Theravance Biopharma Inc (TBPH) | $884.18M | 95.1x | 8.4x | 51.6% | N/A | -20.9% | 0.00% |
| Silence Therapeutics PLC (SLN) | $1.23B | N/A | 882.5x | 0.0% | N/A | 197.2% | 0.00% |
| Design Therapeutics Inc (DSGN) | $670.46M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Prime Medicine, Inc. Common Stock (PRME) | $949.85M | N/A | 105.5x | 0.0% | N/A | 243.9% | 0.00% |
| Alpha Tau Medical Ltd (DRTS) | $1.24B | N/A | N/A | 0.0% | -176.9% | 0.0% | 0.00% |
| Olema Pharmaceuticals Inc (OLMA) | $662.30M | N/A | N/A | 0.0% | -53.8% | 0.0% | 0.00% |
| Surrozen Inc (SRZN) | $602.54M | N/A | 36.1x | 0.0% | N/A | 408.6% | 0.00% |
| Tourmaline Bio Inc. (TRML) | $1.23B | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Peer median | $917.01M | 54.6x | 36.1x | 0.0% | -52.5% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to Monte Rosa Therapeutics, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Rigel Pharmaceuticals Inc (RIGL) | Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat blood disorders, cancer, and rare immune diseases. | RIGL competitors |
| Structure Therapeutics Inc. American Depositary Shares (GPCR) | Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic... | GPCR competitors |
| Oric Pharmaceuticals Inc (ORIC) | ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of cancers. | ORIC competitors |
| Mineralys Therapeutics, Inc. Common Stock (MLYS) | Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular... | MLYS competitors |
| Theravance Biopharma Inc (TBPH) | Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and markets organ-selective drugs in the United States, Europe... | |
| Silence Therapeutics PLC (SLN) | Silence Therapeutics plc, a biotechnology company, is focused on the discovery and development of new ribonucleic acid (RNA) therapies in hematology... | SLN competitors |
| Design Therapeutics Inc (DSGN) | Design Therapeutics, Inc. develops therapies for the treatment of degenerative disorders caused by nucleotide repeat expansions. | DSGN competitors |
| Prime Medicine, Inc. Common Stock (PRME) | Prime Medicine, Inc. is a pioneering biotechnology company specializing in genetic medicine through its proprietary Prime Editing technology... | PRME competitors |
| Alpha Tau Medical Ltd (DRTS) | Alpha Tau Medical Ltd., a clinical-stage oncology therapies company, is engaged in the research, development... | DRTS competitors |
| Olema Pharmaceuticals Inc (OLMA) | Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development... | OLMA competitors |
| Surrozen Inc (SRZN) | Surrozen Inc. is a clinical-stage biopharmaceutical company at the forefront of developing innovative therapeutics using its proprietary SIRPa-IgG platform... | SRZN competitors |
| Tourmaline Bio Inc. (TRML) | Tourmaline Bio Inc. is a pioneering biotechnology firm dedicated to developing cutting-edge cell therapies targeting severe and life-threatening conditions... |
Frequently Asked Questions About GLUE
Who are Monte Rosa Therapeutics' main competitors?
The companies most similar to Monte Rosa Therapeutics include Rigel Pharmaceuticals (RIGL), Structure Therapeutics Inc. American Depositary Shares (GPCR), Oric Pharmaceuticals (ORIC), Mineralys Therapeutics, Inc. Common Stock (MLYS) and Theravance Biopharma (TBPH), listed from the closest match.
Who is Monte Rosa Therapeutics' biggest competitor?
Structure Therapeutics Inc. American Depositary Shares (GPCR) is the largest of the similar companies at $1.43B; Rigel Pharmaceuticals (RIGL) is the closest match by business profile, size, sector and industry.
How does GLUE stock compare with its competitors?
GLUE's P/S is 13.3x against a peer median of 36.1x; its net margin is -186.2% against a peer median of 0.0%.
Which of Monte Rosa Therapeutics' competitors pays a higher dividend?
Monte Rosa Therapeutics pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Monte Rosa Therapeutics bigger than its competitors?
No. Monte Rosa Therapeutics is 10th by market cap among the 13 companies on this page; the largest is Structure Therapeutics Inc. American Depositary Shares (GPCR) at $1.43B.
GLUE pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors